HPV-DNA与TCT联合检测在宫颈早期病变筛查中的相关性研究  

Clinical Relevance of Combined Detection of HPV-DNA and TCT for Early Cervical Lesions

作　　者：兰旭青[1] 王默琪[1] 王琳[1] 

机构地区：[1]解放军第253医院免疫中心,内蒙古呼和浩特010051

出　　处：《标记免疫分析与临床》2012年第5期271-272,共2页Labeled Immunoassays and Clinical Medicine

摘　　要：目的探讨新柏氏液基薄层细胞学(TCT)技术联合HPV-DNA检测在宫颈早期病变筛查中的相关性。方法对2008年9月至2011年7月来我院妇科门诊就诊的375例HPV-DNA阳性患者行TCT检测,采取TBS报告方式,将TCT与HPV-DNA结果对进行照分析。结果 375例HPV-DNA阳性患者TCT检查者,结果良性反应性改变273例(72.8%),ASC阳性者84例(22.4%),LSIL阳性6例(1.6%),HSIL阳性12例(3.2%),HPV高危亚型感染率分别为69.23%、92.86%、100%、100%。结论 TCT联合HPV-DNA检测可提高宫颈早期病变的诊断率。Objective To explore the clinical relevance of combined detection of thin prep liquid-based cytology（TCT） and human papillomavirus（HPV） DNA in screening for early cervical lesions.Methods The thin prep liquid-based cytology detection was carried out in 375 cases of HPV-DNA positive patients.The results of TCT and HPV-DNA were analyzed by TBS reporting method.Results The number of benign reactive changes was 273（72.8%） in TCT examiner of 375 cases of HPV-DNA positive patients.The number of ASC positive was 84 cases（22.4%）,LSIL positive was 6 cases（1.6%） and HSIL-positive was 12 cases（3.2%）.The infection rates of sub-type of HPV high-risk were 69.23%,92.86%,100% and 100% respectively.Conclusion The combined detection of TCT with HPV-DNA could improve the diagnosis rate for early cervical lesions.

关 键 词：液基薄层细胞检测技术(TCT检) 人乳头瘤病毒(HPV) 宫颈早期病变 

分 类 号：R737.33[医药卫生—肿瘤]